Despite recalls, providers appear to
want smart pumps
OREM, Utah – New FDA regulations
and widespread recalls – including an order to recall-and-destroy the
Baxter COLLEAGUE – have done little to dampen demand for smart infusion
pumps, according to a new report from KLAS, a research company.
For the new report, Smart Pumps 2011: The FDA Steps in – Provider
Reactions to Market Turmoil, KLAS interviewed 116 healthcare providers
about how recent FDA actions were affecting them specifically and the
smart pump market as a whole. Every smart pump vendor has been involved
in a recall (in the United States) at least once in the past 24 months.
Nevertheless, healthcare providers are not staying out of the market.
Only 9 percent of providers said these events will delay their current
“The vast majority of smart pumps users are proceeding cautiously, but
on much the same timeline as had been previously planned,” said Coray
Tate, KLAS research director and author of the report. “Providers who
plan to make a change in the next two years are largely doing so because
of the age of their pumps. Regardless of the recent recall events,
providers do not feel they can stay out of the market-as it is simply
time to replace their pumps.”
According to the report, few providers are leaving their smart pumps
vendors because of recall issues. Even among Baxter COLLEAGUE customers,
only about half indicated that the recall has harmed their overall
opinion of Baxter.
“Interestingly, although providers bemoan the time and resources they
must use to deal with recalls, they have largely come to accept recalls
as part of the experience of owning smart pumps,” Tate remarked. “Simply
put, providers generally do not feel the grass will be greener if they
The report also gathered reactions to the FDA Infusion Pump Improvement
Initiative, enacted last year. Most providers view the more stringent
standards required for FDA approval as necessary, and 65 percent expect
the FDA actions to result in safer pumps. However, providers say the
increased safety comes at a cost: Many expect the extended testing and
review procedures to slow enhancement releases-and possibly increase
Baxter COLLEAGUE users were affected more acutely by the recent recall
and are forced to replace their pumps by July 2012. As part of Smart
Pumps 2011: The FDA Steps in – Provider Reactions to Market Turmoil
report, KLAS researched which pumps are likely to fill the void left by
the recalled Baxter COLLEAGUEs. Baxter Sigma is being considered most
often, in 77 percent of deals, likely because Baxter has offered to
replace COLLEAGUE with Sigma at no cost. CareFusion is second in
mindshare, followed by Hospira and B. Braun.
For more information about the smart pumps market, as well as the
strengths and weaknesses of participating vendors, Smart Pumps 2011: The
FDA Steps in – Provider Reactions to Market Turmoil is available to
healthcare providers online for a significant discount off the standard
retail price. To purchase, healthcare providers and vendors can visit
KLAS is a research firm specializing in monitoring and reporting the
performance of healthcare vendors. KLAS’ mission is to improve delivery,
by independently measuring vendor performance for the benefit of our
healthcare provider partners, consultants, investors, and vendors.
Working together with executives from over 4500 hospitals and over 2500
clinics, KLAS delivers timely reports, trends, and statistics, which
provide a solid overview of vendor performance in the industry. KLAS
measures performance of software, professional services, and medical
equipment vendors. For more information, go to
or call 1-800-920-4109 to speak with a KLAS representative.
Posted February 10, 2011